Zi-Yi Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zi-Yi Wu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Hua Jia
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
3 shared publications Chang-Mi Deng
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
2 shared publicationsDa-Wei Yang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
2 shared publicationsFang Wang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
2 shared publications- Jianbing Mu
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, USA
2 shared publications Jiang-Bo Zhang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8) , e72166
Upper Versus Middle‐Neck Involvement in TNM ‐9 Stage IB Nasopharyngeal Carcinoma: Implications for De‐Escalation and Intensification Strategies
Background: TNM‐9 Stage IB nasopharyngeal carcinoma (NPC) encompasses markedly heterogeneous risk profiles, yet lacks reliable biomarkers to guide the choice between de‐escalation and intensification strategies. This study aimed to explore the prognostic significance of upper‐ and middle‐neck nodal involvement (UNI and MNI) in this population and how it affects treatment outcomes and prognosis. Methods: Patients with Stage IB NPC treated between June 2016 and December 2019 at our institution were included. Nodal levels were classified into UNI and MNI. Survival outcomes, including overall survival (OS), progression‐free survival (PFS), distant control (DC), and regional control (RC), were analyzed. Results: A total of 370 patients were analyzed, with 257 (69.5%) classified in the UNI group and 113 (30.5%) in the MNI group, respectively. MNI was found to be associated with significantly worse prognosis compared to UNI. Specifically, the MNI group had lower 5‐year OS (91.1% vs. 98.8%, p < 0.001), PFS (78.6% vs. 95.6%, p < 0.001), DC (90.2% vs. 98.8%, p < 0.001), and RC (93.3% vs. 98.4%, p = 0.005) than the UNI group. Association analysis revealed that nodal level was significantly associated with other known adverse prognostic factors, including the maximum diameter of positive lymph nodes, matted nodes, and high EBV‐DNA levels (all p < 0.001). Crucially, after multivariate adjustment, nodal level is the only independent prognostic factor. Conclusion: The nodal level was a critical factor in predicting patient outcomes in Stage IB NPC. These findings are hypothesis‐generating: UNI patients may represent a candidate population for prospective de‐escalation trials, whereas MNI patients may warrant evaluation of intensified or novel strategies in future studies. Prospective validation is required before any change in clinical management.
- 6 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8) , e72166
Open AccessUpper Versus Middle‐Neck Involvement in TNM ‐9 Stage IB Nasopharyngeal Carcinoma: Implications for De‐Escalation and Intensification Strategies
Background: TNM‐9 Stage IB nasopharyngeal carcinoma (NPC) encompasses markedly heterogeneous risk profiles, yet lacks reliable biomarkers to guide the choice between de‐escalation and intensification strategies. This study aimed to explore the prognostic significance of upper‐ and middle‐neck nodal involvement (UNI and MNI) in this population and how it affects treatment outcomes and prognosis. Methods: Patients with Stage IB NPC treated between June 2016 and December 2019 at our institution were included. Nodal levels were classified into UNI and MNI. Survival outcomes, including overall survival (OS), progression‐free survival (PFS), distant control (DC), and regional control (RC), were analyzed. Results: A total of 370 patients were analyzed, with 257 (69.5%) classified in the UNI group and 113 (30.5%) in the MNI group, respectively. MNI was found to be associated with significantly worse prognosis compared to UNI. Specifically, the MNI group had lower 5‐year OS (91.1% vs. 98.8%, p < 0.001), PFS (78.6% vs. 95.6%, p < 0.001), DC (90.2% vs. 98.8%, p < 0.001), and RC (93.3% vs. 98.4%, p = 0.005) than the UNI group. Association analysis revealed that nodal level was significantly associated with other known adverse prognostic factors, including the maximum diameter of positive lymph nodes, matted nodes, and high EBV‐DNA levels (all p < 0.001). Crucially, after multivariate adjustment, nodal level is the only independent prognostic factor. Conclusion: The nodal level was a critical factor in predicting patient outcomes in Stage IB NPC. These findings are hypothesis‐generating: UNI patients may represent a candidate population for prospective de‐escalation trials, whereas MNI patients may warrant evaluation of intensified or novel strategies in future studies. Prospective validation is required before any change in clinical management.
- Open Access
- 27 August 2024
- Published by Wiley in Cancer Science
- Vol. 115 (11) , 3776-3787
Plasma ofCS‐modified CD44 predicts the survival of patients with lung cancer
Plasma levels of oncofetal chondroitin sulfate (ofCS)‐modified CD44 have emerged as a promising biomarker for multi‐cancer detection. Here, we explored its potential to predict the survival of patients with lung cancer. A prospective observational cohort was conducted involving 274 newly diagnosed patients with lung cancer at the Sun Yat‐sen University Cancer Center from 2013 to 2015. The plasma levels of ofCS‐modified CD44 were measured, and Cox regression analysis was performed to assess the association between plasma‐modified CD44 levels and overall survival (OS) as well as other prognostic outcomes. Prognostic nomograms were constructed based on plasma ofCS‐modified CD44 levels to predict survival outcomes for patients with lung cancer. Patients with high expression ofCS‐modified CD44 exhibited significantly worse outcomes in terms of OS (HR = 1.61, 95%CI = 1.13–2.29, p = 0.009) and progression‐free survival (PFS). These findings were consistent across various analyses. The concordance index of the prognostic nomogram for predicting OS in both the training set and validation set were 0.723 and 0.737, respectively. Additionally, time‐dependent receiver operating characteristic (ROC) curves showed that the nomogram could serve as a useful tool for predicting OS in patients with lung cancer. Plasma ofCS‐modified CD44 may serve as an independent prognosis marker for patients with lung cancer. Further validation of its predictive value could enhance prognostic assessment and guide personalized treatment strategies for patients with lung cancer.
- 27 August 2024
- Published by Wiley in Cancer Science
- Vol. 115 (11) , 3776-3787
Open AccessPlasma ofCS‐modified CD44 predicts the survival of patients with lung cancer
Plasma levels of oncofetal chondroitin sulfate (ofCS)‐modified CD44 have emerged as a promising biomarker for multi‐cancer detection. Here, we explored its potential to predict the survival of patients with lung cancer. A prospective observational cohort was conducted involving 274 newly diagnosed patients with lung cancer at the Sun Yat‐sen University Cancer Center from 2013 to 2015. The plasma levels of ofCS‐modified CD44 were measured, and Cox regression analysis was performed to assess the association between plasma‐modified CD44 levels and overall survival (OS) as well as other prognostic outcomes. Prognostic nomograms were constructed based on plasma ofCS‐modified CD44 levels to predict survival outcomes for patients with lung cancer. Patients with high expression ofCS‐modified CD44 exhibited significantly worse outcomes in terms of OS (HR = 1.61, 95%CI = 1.13–2.29, p = 0.009) and progression‐free survival (PFS). These findings were consistent across various analyses. The concordance index of the prognostic nomogram for predicting OS in both the training set and validation set were 0.723 and 0.737, respectively. Additionally, time‐dependent receiver operating characteristic (ROC) curves showed that the nomogram could serve as a useful tool for predicting OS in patients with lung cancer. Plasma ofCS‐modified CD44 may serve as an independent prognosis marker for patients with lung cancer. Further validation of its predictive value could enhance prognostic assessment and guide personalized treatment strategies for patients with lung cancer.
- Open Access
- 6 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection
Various biomarkers targeting cell-free DNA (cfDNA) and circulating proteins have been tested for pan-cancer detection. Oncofetal chondroitin sulfate (ofCS), which distinctively modifies proteoglycans (PGs) of most cancer cells and binds specifically to the recombinant Plasmodium falciparum VAR2CSA proteins (rVAR2), is explored for its potential as a plasma biomarker in pan-cancer detection. To quantitate the plasma ofCS/ofCSPGs, we optimized an ELISA using different capture/detection pairs (rVAR2/anti-CD44, -SDC1, and -CSPG4) in a case-control study with six cancer types. We show that the plasma levels of ofCS/ofCSPGs are significantly higher in cancer patients (P values, 1.2 × 10−2 to 4.4 × 10−10). Validation studies are performed with two independent cohorts covering 11 malignant tumors. The individuals in the top decile of ofCS-CD44 have more than 27-fold cancer risk (OR = 27.8, 95%CI = 18.8–41.4, P = 2.72 × 10−62) compared with the lowest 20%. Moreover, the elevated plasma ofCS-CD44 could be detected at the early stage of pan-cancer with strong dose-dependent odds risk prediction.
- 6 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-12
Open AccessEstablishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection
Various biomarkers targeting cell-free DNA (cfDNA) and circulating proteins have been tested for pan-cancer detection. Oncofetal chondroitin sulfate (ofCS), which distinctively modifies proteoglycans (PGs) of most cancer cells and binds specifically to the recombinant Plasmodium falciparum VAR2CSA proteins (rVAR2), is explored for its potential as a plasma biomarker in pan-cancer detection. To quantitate the plasma ofCS/ofCSPGs, we optimized an ELISA using different capture/detection pairs (rVAR2/anti-CD44, -SDC1, and -CSPG4) in a case-control study with six cancer types. We show that the plasma levels of ofCS/ofCSPGs are significantly higher in cancer patients (P values, 1.2 × 10−2 to 4.4 × 10−10). Validation studies are performed with two independent cohorts covering 11 malignant tumors. The individuals in the top decile of ofCS-CD44 have more than 27-fold cancer risk (OR = 27.8, 95%CI = 18.8–41.4, P = 2.72 × 10−62) compared with the lowest 20%. Moreover, the elevated plasma ofCS-CD44 could be detected at the early stage of pan-cancer with strong dose-dependent odds risk prediction.
- Open Access
- 15 September 2022
- Published by Elsevier in EBioMedicine
- Vol. 84, 104267
Rare POLN mutations confer risk for familial nasopharyngeal carcinoma through weakened Epstein-Barr virus lytic replication
- 15 September 2022
- Published by Elsevier in EBioMedicine
- Vol. 84, 104267
Open AccessRare POLN mutations confer risk for familial nasopharyngeal carcinoma through weakened Epstein-Barr virus lytic replication